The Global Market for Stem Cell Technologies is Forecast to Reach US$29.3 Billion by 2024

Rising Demand for Regenerative Medicine Aided by the Growing Burden of Chronic Diseases to Drive the Global Stem Cells Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, market size and demand forecasts on the global Stem Cells market. The global market for Stem Cell technologies is forecast to reach US$29.3 billion by 2024, driven by factors such as continuous discovery of new sources of stem cells, innovative new methods for their acquisition and harvesting, increasing incidence of chronic diseases and rising demand for regenerative medicine.

Growing demand for stem cells in regenerative therapy, aided by increasing incidence of chronic diseases, is expected to drive the stem cells market. Most of the revenue from regenerative medicine is attributable to demand for stem cell therapy in the treatment of neurological disorders, such as Parkinson’s disease, Huntington’s chorea, and suchlike. Robust investments in healthcare R&D also boosts the market. Other key drivers in the market include rising government support for the medical sector, growing personal disposable incomes presence of health insurance, and increasing medical tourism to low cost countries. U.S., Korea, and China represent heavy investors in clinical investigations using stem cell products, accounting for a major share of stem cell clinical trials conducted worldwide.

 While embryonic stem cells have been used for their superior efficacy and wide appeal, adult stem cells are increasingly gaining favour among researchers because they are sourced ethically and are less susceptible to immune rejection. There are currently several research studies seeking to validate the efficiency of adult tissue-derived stem cells when used in lieu of embryonic stem cells. Induced Pluripotent Stem Cells (iPSCs) represent another area revolutionizing the stem cell research space. The recent years witnessed major developments in the iPSC space, in terms of biobanking, differentiation technologies and applications in clinical research and potential therapeutics. iPSC thus represents a major trend that offers promise for the treatment of many incurable diseases.

Several human trials with Mesenchymal Stem Cells (MSCs), which are cells extracted from fat, bone marrow and other tissues, are also in progress. These cells are capable of modulating inflammatory response and the immune system, and feature potential capability to treat a number of conditions including autoimmune disorders, arthritis, and graft vs host disease in bone marrow transplant patients. Neural stem cells extracted from either adult or foetal brain tissue are also under testing for rare inherited brain disorders and also for certain common conditions such as spinal cord injury in humans.

As stated by the new market research report on Stem Cells, the United States dominates the market for stem cell technologies supported by huge government funding and the ensuing increase in the number of stem cell clinical trials underway for a wide range of diseases. Asia-Pacific ranks as the fastest growing market led by factors such as growing interest of Southeast Asian countries in understanding and commercializing stem cells for a range of crippling and degenerative diseases; policy led development of networking infrastructure for stem cell research, stem cell banking and stem cell tourism; adoption of free enterprise model by Asian countries to encourage public and private funding and participation; and growing focus on life sciences research to manage the growing healthcare burden in the region.   

Key players in the market include Athersys Inc., Apceth GmbH & Co. KG, AVIVA BioSciences Corporation, BioE Inc., Bone Therapeutics SA, Cesca Therapeutics Inc., Cryo-Cell International Inc., Cytori Therapeutics Inc., ESI BIO, Gamida Cell Ltd., Holostem Terapie Avanzate, International Stem Cell Corp., Kangstem Biotech. Ltd., Lonza Group Ltd., Mesoblast Ltd., Neuralstem Inc., Nuvasive Inc., Osiris Therapeutics Inc., OncoMed Pharmaceuticals Inc., PROMETHERA Biosciences S.A.N.V,  Reliance Life Sciences, ReNeuron Group Plc., STEMCELL Technologies Inc., Stemedica Cell Technologies Inc., Stempeutics Research Pvt. Ltd., Takara Bio USA Inc., TiGenix NV, U.S Stem Cell Inc., and ViaCord, among others.

The research report titled “Stem Cells: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and other strategic activities of major companies. The report provides market estimates and projections in dollars for all major geographic markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World.


Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.

Comments

Popular posts from this blog

The Global Market for Surfing is Projected to Reach US$9.5 Billion by 2022

The Global Market for Private Tutoring Services is Forecast to Reach US$227 Billion by 2022